Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Angina

Angina

Part of Myocardial ischemia

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Angina

27 trials tracked for Angina: 8 in phase 3 or 4 and 2 with published results. The most-cited published study has 50 citations.

27Trials tracked
8Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 4 Phase 3 4 Phase 2 5 Other / NA 14
  1. Phase 3 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD Completed · 50 cited
  2. Phase 4 Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina Completed · 25 cited
  3. Phase 4 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Completed
  4. Phase 4 Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention Completed
  5. Phase 4 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow Completed
  6. Phase 3 Myocardial Ischemia and Transfusion Pilot Completed
Show 21 more trials
  1. Phase 3 Ranolazine and Pulmonary Hypertension Completed
  2. Phase 3 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Completed
  3. Phase 2 Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention Completed
  4. Phase 2 Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) Completed
  5. Phase 2 Ranolazine Among Unrevascularized Chronic Stable Angina Patients Completed
  6. Phase 2 Aspirin Resistance and Percutaneous Coronary Intervention (PCI) Completed
  7. Phase 2 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) Completed
  8. N/A Plasmonic Nanophotothermal Therapy of Atherosclerosis Completed
  9. N/A Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases Completed
  10. N/A Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart) Completed
  11. N/A Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina Completed
  12. N/A Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques Completed
  13. N/A PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements Completed
  14. N/A XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan Completed
  15. N/A Comparative Effectiveness of Decision Aids for Stable Chest Discomfort Completed
  16. N/A Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity) Completed
  17. N/A XIENCE PRIME Japan Post-Marketing Surveillance (PMS) Completed
  18. N/A Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe Completed
  19. N/A Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes Completed
  20. N/A MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms Completed
  21. N/A MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms Completed

Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Angina: what the trials found

Nicorandil has been shown to significantly reduce the number of myocardial ischemia attacks within a 24-hour period compared to control groups (p<0.0001) 1. Several trials have evaluated Nicorandil in various phases for angina management [1, 4].

Ranolazine was shown to improve angina symptoms (p=0.0013) 6, although it did not significantly impact the 6-minute walk test (p=0.09) or quality of life scores (p=0.37) 6. Other trials evaluated Ranolazine in various phases for this condition [3, 5, 12].

Red blood cell transfusion was associated with significant changes in hemoglobin concentration and transfusion rates (p<0.001) 7.

Rivaroxaban 2.5 mg demonstrated a statistically significant reduction in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (p=0.020) 8. Additionally, it showed a significant reduction in the composite of all-cause death, myocardial infarction, or stroke (p=0.016) 8. However, no significant difference was found regarding the composite of cardiovascular death, myocardial infarction, ischemic stroke, or TIMI major bleeding events not associated with CABG (p=0.320) 8.

Recent results — preliminary, needs further review

  • Erenumab showed no significant difference in time to onset of exercise-induced angina (p=0.69) or time to onset of ≥ 1 mm ST-segment depression (p=0.59) 10.
  • Adult stem cells did not show statistically significant changes in maximal oxygen consumption (p=0.169), left ventricular end systolic volume (p=0.856), or reversible defect size (p=0.835) 13.

For the clinician treating this condition

  • Nicorandil is associated with a significant reduction in the frequency of myocardial ischemia attacks within 24 hours.
  • Ranolazine is effective for improving clinical angina symptoms, though its impact on physical exercise tests and subjective quality of life metrics was not statistically confirmed.
  • Rivaroxaban at 2.5 mg significantly reduces composite endpoints involving cardiovascular death, MI, or stroke.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Residual angina occurs in 42.2% of patients after anatomic complete revascularization for chronic coronary disease
Cardiology RCT
Residual angina occurs in 42.2% of patients after anatomic complete revascularization for chronic coronary disease Residual angina affects over 40% of patients after complete heart artery treatment
This randomized controlled trial evaluated symptomatic patients with chronic coronary disease undergoing invasive management. At six months,…
More than 40% of patients still have chest pain six months after complete heart artery treatment, impacting daily life and medication needs.
May 19, 2026
Adjunctive Xuefu Zhuyu oral liquid lowers angina pain scores and nitroglycerin use in stable angina
Rheumatology RCT
Adjunctive Xuefu Zhuyu oral liquid lowers angina pain scores and nitroglycerin use in stable angina Herbal liquid reduces chest pain for stable angina patients
This randomized controlled trial evaluated Xuefu Zhuyu oral liquid in 148 patients with stable angina across six hospitals in China.
A simple herbal liquid added to standard heart treatment may lower chest pain and reduce the need for rescue medication in patients with sta…
Frontiers Apr 29, 2026
CMR-guided management improves treatment satisfaction in patients with ANOCA
Cardiology RCT
CMR-guided management improves treatment satisfaction in patients with ANOCA Does better imaging help patients with chest pain feel more satisfied with their care?
In this randomized controlled trial of 250 patients with suspected ANOCA, CMR-guided management significantly increased global treatment sat…
Advanced heart scans helped patients with chest pain feel much more satisfied with their care and receive better medications after six month…
Apr 19, 2026
Residual global μQFR assessment associated with 3-year MACE risk in acute coronary syndrome patients
Cardiology RCT
Residual global μQFR assessment associated with 3-year MACE risk in acute coronary syndrome patients Better Heart Maps Predict Long-Term Survival
This post hoc analysis of a randomized controlled trial evaluated 2,428 acute coronary syndrome patients over 36.0 months.
A new heart map predicts long-term survival just as well as expensive pressure wires, helping doctors spot high-risk patients after stent pr…
Apr 16, 2026
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years
Cardiology RCT
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years Intensive heart medication did not reduce major events in women with suspected ANOCA
This randomized controlled trial enrolled 2,476 women with suspected ANOCA/INOCA across 71 US sites.
Intensive heart medication did not reduce major events in women with suspected ANOCA, finding that aggressive treatment offered no benefit o…
Apr 6, 2026
Robotic PCI system shows feasibility in small study of complex coronary lesions
Cardiology
Robotic PCI system shows feasibility in small study of complex coronary lesions Can a robot help fix complex heart blockages? An early test shows promise
A prospective single-center single-arm trial of 20 patients with unstable angina and complex coronary anatomy evaluated the ETcath200 roboti…
A new robot system helped doctors successfully clear complex heart blockages in 16 out of 20 patients without major complications during an …
Apr 2, 2026
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial
Cardiology RCT
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial For heart attacks with clear arteries, does personalized treatment help? New trial shows it improves chest pain
In the PROMISE RCT (n=92), stratified treatment for MINOCA significantly improved angina status at 12 months vs standard care (mean SAQSS di…
Patients with heart attacks and clear arteries got better chest pain and quality of life after doctors found and treated the specific cause …
Mar 30, 2026

Questions about Angina

Did intensive medical treatment fail to help women with suspected ANOCA?

Intensive medical treatment did not reduce heart events in women with suspected ANOCA, but using cardiac MRI to guide care improved satisfaction and diagnosis accuracy.

Full answer →
Will intensive medical treatment reduce my major adverse cardiovascular events?

For women with ANOCA/INOCA, intensive medical treatment did not reduce major adverse cardiovascular events over 2.5 years compared to usual care.

Full answer →